Kunduracı Merve Sena, Kırık Furkan, Onur Ismail Umut, Onur Ozge Sahmelikoglu, Karsidag Cagatay, Yigit Fadime Ulviye, Erkiran Murat
Department of Ophthalmology, University of Health Sciences Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey.
Department of Ophthalmology, Bezmialem Vakif University, Istanbul, Turkey.
Eye (Lond). 2025 Jan;39(1):94-101. doi: 10.1038/s41433-024-03381-x. Epub 2024 Oct 8.
To evaluate the ocular effects of "Bonzai", a synthetic cannabinoid (SC), in seropositive and seronegative users.
Sixty eyes of 60 consecutive male patients with a history of "Bonzai" use and 30 eyes of 30 age-matched male healthy controls were enrolled in this case-control study. Patients with past "Bonzai" use were grouped as seropositive (n:30) and seronegative (n:30) according to urine toxicology tests. All groups were compared for blood pressures, intraocular pressure, foveal and parafoveal retinal thicknesses, subfoveal and parafoveal choroidal thicknesses, measurements of the peripapillary retinal nerve fibre layer (RNFL), and macular ganglion cell complex (GCC), subfoveal total choroidal, luminal and stromal areas, and choroidal vascularity index (CVI).
No differences were noted in blood pressures between the groups (p > 0.05). The mean intraocular pressure was significantly lower in the seropositive group than in the other groups (p < 0.001). Foveal and retinal thicknesses, RNFL, and GCC measurements did not differ between the groups (p > 0.05). Subfoveal and parafoveal choroidal thicknesses and areas were lower in the seropositive group than in the other groups (p < 0.001, for all). CVI increased in both groups with "Bonzai" use compared to the control group (p < 0.001, for all).
This study indicates that intraocular pressure may decrease, and choroidal changes may be observed in SC users. Further clinical studies with a larger sample size, especially using purified SC for therapeutic purposes, are needed to confirm the present findings, and further histopathologic studies are required to clarify the changes in the choroid despite SC seronegativity.
NCT06235346.
评估合成大麻素“邦仔”（Bonzai）对血清学阳性和血清学阴性使用者的眼部影响。
本病例对照研究纳入了60例有“邦仔”使用史的连续男性患者的60只眼以及30例年龄匹配的男性健康对照者的30只眼。既往有“邦仔”使用史的患者根据尿液毒理学检测分为血清学阳性组（n = 30）和血清学阴性组（n = 30）。比较所有组的血压、眼压、黄斑中心凹和黄斑旁视网膜厚度、黄斑中心凹下和黄斑旁脉络膜厚度、视乳头周围视网膜神经纤维层（RNFL）测量值、黄斑神经节细胞复合体（GCC）、黄斑中心凹下脉络膜总面积、管腔面积和基质面积以及脉络膜血管指数（CVI）。
各组间血压无差异（p > 0.05）。血清学阳性组的平均眼压显著低于其他组（p < 0.001）。各组间黄斑中心凹和视网膜厚度、RNFL以及GCC测量值无差异（p > 0.05）。血清学阳性组的黄斑中心凹下和黄斑旁脉络膜厚度及面积低于其他组（所有p < 0.001）。与对照组相比，两组使用“邦仔”后CVI均增加（所有p < 0.001）。
本研究表明，合成大麻素使用者可能出现眼压降低以及脉络膜变化。需要进行更大样本量的进一步临床研究，尤其是使用纯化的合成大麻素用于治疗目的，以证实目前的发现，并且需要进一步的组织病理学研究来阐明尽管血清学阴性但脉络膜的变化。
NCT06235346。
